Q1. Could you start by giving us a brief overview of your professional background, particularly focusing on your expertise in the industry?

I currently serve as Enterprise Capabilities Lead for Roche Pharma, having previously held senior leadership roles, including Head of Global End-to-End Planning at Biogen and Senior Director of Global Forecasting at Bristol Myers Squibb. My career encompasses extensive experience in global supply chain transformations, forecasting centers of excellence, and S&OP design across the life sciences and FMCG sectors, including tenures at Mars Inc. and SABMiller. I specialize in leveraging data analytics and digital transformation, including AI/genAI, to elevate Integrated Business Planning (IBP) and build resilient, patient-centric supply chains.
 

Q2. How is Integrated Business Planning (IBP) evolving from a coordination tool to a true value-creation engine in pharma?

IBP is shifting from a basic volume-matching and coordination exercise to a dynamic, financially integrated operating model. In the pharma industry, we are increasingly leveraging big data and predictive analytics to connect patient demand signals directly with end-to-end supply networks. By incorporating rapid scenario planning and real-time financial alignment, IBP now serves as a strategic compass that drives profitability, resource optimization, and enterprise agility rather than merely operational consensus.

Q3. Do you see traceability becoming a competitive differentiator, or will it remain a compliance-driven cost center?

While traceability was born out of regulatory mandates like the DSCSA and FMD, it has rapidly evolved into a competitive differentiator. True forensic visibility across the supply chain enables us to proactively mitigate disruptions, optimize inventory placement, shorten End-to-End lead time, and guarantee product authenticity. Companies that harness this data effectively unlock bottom-line savings, build immense trust with healthcare providers, and ensure seamless patient outcomes.
 

Q4. How are pharma companies rethinking global network design in light of geopolitical risks and localization pressures? 

Pharma supply chains are pivoting from purely cost-driven, heavily centralized hubs toward agile, "glocalized" models. Geopolitical tensions, trade complexities, and localization pressures are forcing organizations to build redundant, regionalized capacity. This means near-shoring critical manufacturing, embracing multi-sourcing strategies, and prioritizing resilience and risk mitigation over traditional cost arbitrage.
 

Q5. In what types of decisions has AI delivered the most strategic value, and where does it still struggle to influence outcomes meaningfully? 

AI delivers immense value in predictive demand forecasting, anomaly detection (e.g., Masterdata), and automating repetitive, high-volume planning tasks. It excels at identifying patterns across massive datasets to optimize inventory levels and reduce waste. However, AI still struggles with highly ambiguous, unquantifiable variables - such as interpreting the nuances of sudden geopolitical shifts, navigating true "black swan" disruptions, or replacing the human intuition and relationship-building required to align stakeholders during complex strategic trade-offs.
 

Q6. How do you see purchasing criteria evolving as AI, automation, and digital ecosystems become more embedded in supply chains? 

Procurement is shifting its focus from simple unit cost reduction to total ecosystem value. As digital supply networks mature, purchasing criteria increasingly prioritize a vendor's technological interoperability, data transparency, and agility. Partners are now evaluated on their ability to seamlessly integrate their data into our AI frameworks, as well as their proven commitment to sustainability and uninterrupted supply resilience.
 

Q7. If you were an investor looking at companies within the space, what critical question would you pose to their senior management?

I would ask: “How are you structurally breaking down internal data silos to ensure your investments in APS (advanced planning solutions), AI, and automation (e.g., RPA) actually drive End-to-End enterprise value, rather than just creating faster, isolated departmental efficiencies?” The true measure of an organization's digital maturity is how well its technology bridges the gaps sustainably between commercial, finance, and supply chain operations to influence holistic business outcomes.